Smedsrød B, Johansson S, Pertoft H
Biochem J. 1985 Jun 1;228(2):415-24. doi: 10.1042/bj2280415.
Intravenously administered 125I-labelled monomeric alpha 1 chains (125I-alpha 1) of collagen type I were rapidly cleared and degraded by the liver of rats. Isolation of the liver cells after injection of the label revealed that the uptake per liver endothelial cell equalled the uptake per Kupffer cell, whereas the amount taken up per hepatocyte was negligible. The uptake of 125I-alpha 1 in cultured cells was 10 times higher per liver endothelial cell than per Kupffer cell. The ligand was efficiently degraded by cultures of both cell types. However, spent medium from cultures of Kupffer cells, unlike that from cultures of other cells, contained gelatinolytic activity which degraded 125I-alpha 1. The presence of hyaluronic acid, chondroitin sulphate or mannose/N-acetylglucosamine-terminal glycoproteins, which are endocytosed by the liver endothelial cells via specific receptors, did not interfere with binding, uptake or degradation of 125I-alpha 1 by these cells. Unlabelled alpha 1 and heat-denatured collagen inhibited the binding to a much greater extent than did native collagen. The presence of fibronectin or F(ab')2 fragments of anti-fibronectin antibodies did not affect the interaction of the liver endothelial cells, or of other types of liver cells, with 125I-alpha 1. The accumulation of fluorescein-labelled heat-denatured collagen in vesicles of cultured liver endothelial cells is evidence that the protein is internalized. Moreover, chloroquine, 5-dimethylaminonaphthalene-1-sulphonylcadaverine (dansylcadaverine), monensin and cytochalasin B, which impede one or more steps of the endocytic process, inhibited the uptake of 125I-alpha 1 by the liver endothelial cells. Leupeptin, an inhibitor of cathepsin B and 'collagenolytic cathepsins', inhibited the intralysosomal degradation of 125I-alpha 1, but had no effect on the rate of uptake of the ligand. The current data are interpreted as follows. (1) The ability of the liver endothelial cells and the Kupffer cells to sequester circulating 125I-alpha 1 efficiently may indicate a physiological pathway for the breakdown of connective-tissue collagen. (2) The liver endothelial cells express receptors that specifically recognize and mediate the endocytosis of collagen alpha 1(I) monomers. (3) The receptors also recognize denatured collagen (gelatin). (4) Fibronectin is not involved in the binding of alpha 1 to the receptors. (5) Degradation occurs intralysosomally by leupeptin-inhibitable cathepsins.
静脉注射的Ⅰ型胶原蛋白的¹²⁵I标记单体α1链(¹²⁵I-α1)被大鼠肝脏迅速清除并降解。注射标记物后分离肝细胞发现,每个肝内皮细胞的摄取量与每个库普弗细胞的摄取量相等,而每个肝细胞摄取的量可忽略不计。在培养细胞中,¹²⁵I-α1在肝内皮细胞中的摄取量比在库普弗细胞中高10倍。两种细胞类型的培养物都能有效降解该配体。然而,与其他细胞培养物不同 的是,库普弗细胞培养物的用过的培养基含有能降解¹²⁵I-α1的明胶酶活性。透明质酸、硫酸软骨素或甘露糖/N-乙酰葡糖胺末端糖蛋白通过特异性受体被肝内皮细胞内吞,但它们的存在并不干扰这些细胞对¹²⁵I-α1的结合、摄取或降解。未标记的α1和热变性胶原蛋白比天然胶原蛋白在更大程度上抑制结合。纤连蛋白或抗纤连蛋白抗体的F(ab')2片段的存在不影响肝内皮细胞或其他类型肝细胞与¹²⁵I-α1的相互作用。荧光素标记的热变性胶原蛋白在培养的肝内皮细胞囊泡中的积累证明该蛋白被内化。此外,氯喹、5-二甲基氨基萘-1-磺酰尸胺(丹磺酰尸胺)、莫能菌素和细胞松弛素B阻碍内吞过程的一个或多个步骤,它们抑制肝内皮细胞对¹²⁵I-α1的摄取。亮抑蛋白酶肽是组织蛋白酶B和“胶原olytic组织蛋白酶”的抑制剂,它抑制¹²⁵I-α1在溶酶体内的降解,但对配体的摄取速率没有影响。目前的数据解释如下:(1)肝内皮细胞和库普弗细胞有效隔离循环中的¹²⁵I-α1的能力可能表明结缔组织胶原蛋白分解的一种生理途径。(2)肝内皮细胞表达特异性识别并介导胶原α1(I)单体胞吞作用的受体。(3)这些受体也识别变性胶原蛋白(明胶)。(4)纤连蛋白不参与α1与受体的结合。(5)降解通过亮抑蛋白酶肽可抑制的组织蛋白酶在溶酶体内发生。